Free Newsletter
FDA approves new labeling for ADHD med
Novartis Pharmaceuticals announced this morning that the FDA has approved new labeling for Focalin XR (dexmethylphenidate HCl), an extended-release stimulant medication aimed at treating attention deficit hyperactivity disorder (ADHD).
The main differentiator for the new labeling is Focalin XR's 30-minute onset, which Novartis reps say will help with early morning struggles, such as getting ready for school.
The company gained the FDA approval after providing clinical study data showing improvements in attention, deportment and academic productivity in children between the ages of six and 12. The most recent study involved 86 children.
- read the story at RTT News
Related Articles:
Novartis to cut reps, reassign execs
Xoma, Novartis restructure vaccine agreement
Novartis: Data supports pre-pandemic vaccinations
NexMed tanks after Novartis stalls on fungus drug
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: